Timing of Alcohol and Smoking Cessation (TASC): Smoking among Substance Use Patients Screened and Enrolled in a Clinical Trial

Anne M. Joseph, David B. Nelson, Sean M. Nugent, Mark L. Willenbring

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Tobacco dependence is prevalent among alcohol dependent patients, and causes increased morbidity and mortality. Concurrent treatment for these disorders may be advantageous, but there are concerns about adverse effects on alcohol treatment outcomes. The Timing of Alcohol and Smoking Cessation (TASC) Study is a randomized controlled clinical trial to compare the effectiveness of smoking cessation treatment offered concurrently or six months following intensive rehabilitation for alcohol dependence. This paper describes the study design and baseline characteristics of the study population. Participants were current smokers in intensive alcohol dependence treatment, with willingness to consider quitting smoking. Smoking intervention offered behavioral and pharmacological treatment. One thousand nine hundred forty-three patients were screened for enrollment; 499 were eligible and participated (26%). We describe demographic characteristics, smoking behavior and attitudes among participants and nonparticipants toward smoking cessation and drinking. We conclude that there is considerable interest in smoking cessation in alcohol dependent treatment populations, and recruitment to research studies is feasible.

Original languageEnglish (US)
Pages (from-to)87-107
Number of pages21
JournalJournal of Addictive Diseases
Issue number4
StatePublished - 2003

Bibliographical note

Funding Information:
This research is supported by funding from NIAAA RO1AA11124 and the VA Health Services Research and Development Center for Chronic Disease Outcomes Research.


  • Alcohol dependence
  • Concurrent treatment
  • Smoking


Dive into the research topics of 'Timing of Alcohol and Smoking Cessation (TASC): Smoking among Substance Use Patients Screened and Enrolled in a Clinical Trial'. Together they form a unique fingerprint.

Cite this